Lerna Biopharma Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $19.2M

  • Investors
  • 5

Lerna Biopharma General Information

Description

Developer of nucleic acid drug discovery technologies designed to promote tissue regeneration and address unmet needs in chronic diseases. The company offers small-interfering RNA therapeutics, proprietary target discovery, and disease-focused biological mechanisms, enabling biopharmaceutical researchers and specialty drug developers to advance regenerative medicine programs with precise molecular targeting and translational research capability.

Contact Information

Website
www.lernabio.com
Formerly Known As
Cargene Therapeutics, Cargene Biopharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Number 16, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201210
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 4th Floor, Number 16, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201210
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lerna Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 12-Nov-2021 $19.2M Completed Pre-Clinical Trials
2. Accelerator/Incubator 18-May-2021 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Lerna Biopharma’s complete valuation and funding history, request access »

Lerna Biopharma Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

Lerna Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4547843-A2 Inhibitory nucleic acids for itfg1 Pending 28-Jun-2022
US-20260167969-A1 Inhibitory nucleic acids for itfg1 Pending 28-Jun-2022
WO-2024003148-A2 Inhibitory nucleic acids for itfg1 Inactive 28-Jun-2022
WO-2024003148-A3 Inhibitory nucleic acids for itfg1 Inactive 28-Jun-2022
EP-4384528-A2 Galnac-monomers and galnac-nucleic acid conjugates Pending 09-Aug-2021 C12N15/113
To view Lerna Biopharma’s complete patent history, request access »

Lerna Biopharma Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioTrack Capital Venture Capital Minority
Hyfinity Investments Growth/Expansion Minority
Legend Star Corporate Venture Capital Minority
EVX Ventures Venture Capital Minority
LabCentral Accelerator/Incubator
To view Lerna Biopharma’s complete investors history, request access »

Ready to get started?

Request a free trial

Lerna Biopharma FAQs

  • When was Lerna Biopharma founded?

    Lerna Biopharma was founded in 2021.

  • Where is Lerna Biopharma headquartered?

    Lerna Biopharma is headquartered in Shanghai, China.

  • What industry is Lerna Biopharma in?

    Lerna Biopharma’s primary industry is Drug Discovery.

  • Is Lerna Biopharma a private or public company?

    Lerna Biopharma is a Private company.

  • What is Lerna Biopharma’s current revenue?

    The current revenue for Lerna Biopharma is .

  • How much funding has Lerna Biopharma raised over time?

    Lerna Biopharma has raised $19.2M.

  • Who are Lerna Biopharma’s investors?

    BioTrack Capital, Hyfinity Investments, Legend Star, EVX Ventures, and LabCentral have invested in Lerna Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process